In this online CME self-learning program:
In an effort to improve health care quality by fostering collaboration, a consortium of Medication Safety Officers from ASMSO have agreed to work together to enhance the knowledge of, and leading to a reduction in medication administration errors and readmission rates in acute care hospitals.
Why have those particular patient populations been singled out as worthy of attention? The literature suggests that, in each case, they continue to be high risk; errors are more frequent and the potential for catastrophic consequence is higher in these patient populations relative to the general adult population:
Taken together, these observations from the literature and recent guideline updates suggest that gaps in practice exist in these patient populations – gaps that the proposed learning activities will attempt to bridge.
The presentations will be conducted using a case study format identifying areas of safety that have been successful based upon each of the practice areas noted. These presentations will achieve objectives including; Identify factors of the patient population that increase the risk for medication errors, discuss risk reduction strategies for the particular patient population that can be applied to the medication-use process, completing, development of a list of root causes of medication administration errors, determining the economic cost to the system of these errors, development of data collection protocols, and an effort in the participating hospitals to utilize this information to reduce medication administration errors at their facilities.
Agenda
Healthcare professionals including: physicians, mid-level practitioners working in acute care hospitals and other healthcare settings, inpatient-setting medication safety officers, pediatric-specialty pharmacists, pharmacists who otherwise have an interest in pediatric care or whose practice involves pediatric patients, and technicians who are directly or indirectly involved in the medication preparation for pediatric patients.
Commercial Support Disclosure: This program is supported by educational grants from Boehringer Ingelheim and Hospira.
Release Date: January 04, 2013 -- Expiration Date: January 04, 2015
Faculty: Sean O'Neill,
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As an provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure: Sean O'Neill, PharmD reports that she has no relevant financial disclosures.
Disclosures of Educational Planner: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from the commercial supporters of this program.
Disclosures of Educational Planner: Ambra King, PharmD (ASMSO) has no financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Boehrin
ger Ingelheim and Hospira.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.